HIF-1 in Osteoarthritis: from Pathogenesis to Therapeutic Implications

Chu-Yang Zeng,Xi-Feng Wang,Fu-Zhou Hua
DOI: https://doi.org/10.3389/fphar.2022.927126
IF: 5.6
2022-01-01
Frontiers in Pharmacology
Abstract:Osteoarthritis is a common age-related joint degenerative disease. Pain, swelling, brief morning stiffness, and functional limitations are its main characteristics. There are still no well-established strategies to cure osteoarthritis. Therefore, better clarification of mechanisms associated with the onset and progression of osteoarthritis is critical to provide a theoretical basis for the establishment of novel preventive and therapeutic strategies. Chondrocytes exist in a hypoxic environment, and HIF-1 alpha plays a vital role in regulating hypoxic response. HIF-1 alpha responds to cellular oxygenation decreases in tissue regulating survival and growth arrest of chondrocytes. The activation of HIF-1 alpha could regulate autophagy and apoptosis of chondrocytes, decrease inflammatory cytokine synthesis, and regulate the chondrocyte extracellular matrix environment. Moreover, it could maintain the chondrogenic phenotype that regulates glycolysis and the mitochondrial function of osteoarthritis, resulting in a denser collagen matrix that delays cartilage degradation. Thus, HIF-1 alpha is likely to be a crucial therapeutic target for osteoarthritis via regulating chondrocyte inflammation and metabolism. In this review, we summarize the mechanism of hypoxia in the pathogenic mechanisms of osteoarthritis, and focus on a series of therapeutic treatments targeting HIF-1 alpha for osteoarthritis. Further clarification of the regulatory mechanisms of HIF-1 alpha in osteoarthritis may provide more useful clues to developing novel osteoarthritis treatment strategies.
What problem does this paper attempt to address?